盤中異動 | 百濟神州盤中下跌9%,報於83.3港元
2022年3月15日9時30分,百濟神州(HK06160)盤中下跌9%,報於83.3港元,成交額達116.86萬港元,換手率達到0.01%。
3月14日訊,百濟神州(06160.HK)公佈,國家藥監局已附條件批準其抗PD-1抗體藥物百澤安用於治療不可切除或轉移性微衛星高度不穩定型(MSI-H)或錯配修複基因缺陷型(dMMR)的成人晚期實體瘤患者,包括既往接受過氟尿嘧啶類、奧沙利鉑和伊立替康治療後出現疾病進展的晚期結直腸癌患者,及既往治療後出現疾病進展且無滿意替代治療方案的其他晚期實體瘤患者。百澤安已在中國獲批7項適應症。
3月1日,野村:上調百濟神州(06160)評級至“買入”,目標價升至186.85港元。2月28日,國泰君安:維持百濟神州(06160)“增持”評級,目標價降至207.7港元。2月14日,中金:予百濟神州(06160)“跑贏行業”評級,目標價282港元。
最新的財務數據顯示,公司於2021年4季度,營業收入11.76億美元,淨利潤-14.13億美元;營業收入同比增加280.83%,毛利潤同比增加57.62%,淨利潤同比增加11.69%。
盈立趨勢長盈模型最近一次交易信號,2022年3月11日出現觀望信號,觸發價格爲110.3港元(信號僅供參考)。
uSMART智能寫手的信息、數據均來自媒體公開報道,智能寫手不能保證其完全準確,內容僅供參考,不構成投資建議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.